ArticleBreast cancer (Tokyo, Japan)2024

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.